Related references
Note: Only part of the references are listed.Discovery of a new flavin N5-adduct in a tyrosine to phenylalanine variant of D-Arginine dehydrogenase
Archana Iyer et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2022)
Beyond darunavir: recent development of next generation HIV-1 protease inhibitors to combat drug resistance
Arun K. Ghosh et al.
CHEMICAL COMMUNICATIONS (2022)
Synthesis of amide derivatives for electron deficient amines and functionalized carboxylic acids using EDC and DMAP and a catalytic amount of HOBt as the coupling reagents
Arun K. Ghosh et al.
TETRAHEDRON LETTERS (2021)
Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies
Arun K. Ghosh et al.
CHEMMEDCHEM (2019)
Darunavir for the treatment of HIV infection
Vincenzo Spagnuolo et al.
EXPERT OPINION ON PHARMACOTHERAPY (2018)
Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance
Manabu Aoki et al.
MBIO (2018)
Multi-spectroscopic and molecular modeling approaches to elucidate the binding interaction between bovine serum albumin and darunavir, a HIV protease inhibitor
Jie-Hua Shi et al.
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY (2018)
Sub-picomolar Inhibition of HIV-1 Protease with a Boronic Acid
Ian W. Windsor et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2018)
Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS
Arun K. Ghosh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir
Hironori Hayashi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
P2' Benzene Carboxylic Acid Moiety Is Associated with Decrease in Cellular Uptake: Evaluation of Novel Nonpeptidic HIV-1 Protease Inhibitors Containing P2 bis-Tetrahydrofuran Moiety
Ravikiran S. Yedidi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Enhancing Protein Backbone BindinguA Fruitful Concept for Combating Drug-Resistant HIV
Arun K. Ghosh et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Capturing the Reaction Pathway in Near-Atomic-Resolution Crystal Structures of HIV-1 Protease
Chen-Hsiang Shen et al.
BIOCHEMISTRY (2012)
Thirty Years of HIV and AIDS: Future Challenges and Opportunities
Carl W. Dieffenbach et al.
ANNALS OF INTERNAL MEDICINE (2011)
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
Myron S. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Current status and challenges of antiretroviral research and therapy
Jose A. Este et al.
ANTIVIRAL RESEARCH (2010)
Darunavir en primeras líneas. Estudio TITAN
Adrian Curran et al.
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA (2010)
In Vitro Selection of Highly Darunavir-Resistant and Replication-Competent HIV-1 Variants by Using a Mixture of Clinical HIV-1 Isolates Resistant to Multiple Conventional Protease Inhibitors
Yasuhiro Koh et al.
JOURNAL OF VIROLOGY (2010)
Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients
Sandra De Meyer et al.
AIDS (2009)
Design of HIV protease inhibitors targeting protein backbone: An effective strategy for combating drug resistance
Arun K. Ghosh et al.
ACCOUNTS OF CHEMICAL RESEARCH (2008)
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV
Arun K. Ghosh et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
Prevalence of darunavir resistance-associated mutations: Patterns of occurrence and association with past treatment
Yumi Mitsuya et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization
Yasuhiro Koh et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114
Andrey Y. Kovalevsky et al.
JOURNAL OF MOLECULAR BIOLOGY (2006)
Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of HIV protease inhibitors that combat drug resistance
Arun K. Ghosh et al.
CHEMMEDCHEM (2006)
TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates
S De Meyer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains
YF Tie et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
Novel bis-tetrahydrofuranylurethane-containin nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro
Y Koh et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Share Paper
